Royal Bank Of Canada restated their outperform rating on shares of Indivior (LON:INDV) in a research note published on Friday morning, MarketBeat reports. The brokerage currently has a GBX 500 ($6.73) price objective on the specialty pharmaceutical company’s stock.

Other research analysts have also recently issued reports about the company. Stifel Nicolaus reaffirmed a buy rating and set a GBX 400 ($5.38) price objective on shares of Indivior in a research report on Friday, September 15th. Numis Securities reaffirmed a buy rating and set a GBX 470 ($6.33) price objective on shares of Indivior in a research report on Friday, September 15th. Morgan Stanley reissued an equal weight rating and issued a GBX 410 ($5.52) target price on shares of Indivior in a research report on Friday. Jefferies Group upped their target price on Indivior from GBX 358 ($4.82) to GBX 472 ($6.35) and gave the company a buy rating in a research report on Thursday, November 9th. Finally, Citigroup reissued a neutral rating and issued a GBX 280 ($3.77) target price on shares of Indivior in a research report on Thursday, October 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of GBX 472.43 ($6.36).

Indivior (LON INDV) opened at GBX 369.70 ($4.98) on Friday. Indivior has a 1 year low of GBX 246.50 ($3.32) and a 1 year high of GBX 421.50 ($5.67).

COPYRIGHT VIOLATION WARNING: This news story was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://theolympiareport.com/2017/12/05/indivior-indv-receives-outperform-rating-from-royal-bank-of-canada.html.

Indivior Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.